Health ❯ Healthcare ❯ Clinical Trials ❯ Drug Development

Duchenne Muscular Dystrophy

Dyne’s DMD Drug Hits Primary Endpoint in DELIVER REC, Shows Functional Gains

The readout gives Dyne a path to an accelerated approval filing in 2026.

Sarepta Shares Plunge After ESSENCE Phase 3 Miss in Duchenne Trial